scholarly journals Peroxoniobium inhibits leukemia cell growth

RSC Advances ◽  
2018 ◽  
Vol 8 (19) ◽  
pp. 10310-10313 ◽  
Author(s):  
Elene C. Pereira-Maia ◽  
Ivina P. Souza ◽  
Kelen J. R. C. Nunes ◽  
Alexandre A. Castro ◽  
Teodorico C. Ramalho ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cell Growth ◽  
Anticancer Agent ◽  
Leukemia Cell ◽  
New Class

A new class of polyoxoniobate complex has been synthesized and characterized as a novel anticancer agent for photodynamic therapy.

A facile synthesis of formazan dyes conjugated with plasmonic nanoparticles as photosensitizers in photodynamic therapy against leukemia cell line

2018 ◽  
Vol 149 (12) ◽  
pp. 2195-2206 ◽  
Author(s):  
Mohamed E. Khalifa ◽  
Elham A. Elkhawass ◽  
Antoni Pardede ◽  
Masayuki Ninomiya ◽  
Kaori Tanaka ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cell Line ◽  
Leukemia Cell ◽  
Plasmonic Nanoparticles ◽  
Leukemia Cell Line ◽  
Facile Synthesis

scholarly journals In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 758-758
Author(s):  
◽  
Fatima Al-Shahrour ◽  
Kimberly A. Hartwell ◽  
Lisa P Chu ◽  
Jaras Marcus ◽  
...  
Keyword(s):  
Rna Interference ◽  
Cell Growth ◽  
Leukemia Cell ◽  
Leukemia Cells ◽  
Growth And Survival ◽  
Integrin Beta 3 ◽  
Shrna Screen ◽  
Primary Leukemia

Abstract Abstract 758 Primary leukemia stem cells (LSCs) reside in an in vivo microenvironment that supports the growth and survival of malignant cells. Despite the increasing understanding of the importance of niche interactions and primary cell biology in leukemia, many studies continue to focus on cell autonomous processes in artificial model systems. The majority of strategies to-date that attempt to define therapeutic targets in leukemia have relied on screening cell lines in culture; new strategies should incorporate the use of primary disease within a physiologic niche. Using a primary murine MLL-AF9 acute myeloid leukemia (AML) model highly enriched for LSCs, we performed an in vivo short hairpin RNA (shRNA) screen to identify novel genes that are essential for leukemia growth and survival. LSCs infected with pools of shRNA lentivirus were transplanted and grown in recipient mice for 2 weeks, after which bone marrow and spleen cells were isolated. Massively parallel sequencing of infected LSCs isolated before and after transplant was used to quantify the changes in shRNA representation over time. Our in vivo screens were highly sensitive, robust, and reproducible and identified a number of positive controls including genes required for MLL-AF9 transformation (Ctnnb1, Mef2c, Ccna1), genes universally required for cell survival (Ube2j2, Utp18), and genes required in other AML models (Myb, Pbx1, Hmgb3). In our primary and validation screens, multiple shRNAs targeting Integrin Beta 3 (Itgb3) were consistently depleted by more than 20-fold over two weeks in vivo. Follow up studies using RNA interference (RNAi) and Itgb3−/− mice identified Itgb3 as essential for murine leukemia cells growth and transformation in vivo, and loss of Itgb3 conferred a statistically significant survival advantage to recipient mice. Importantly, neither Itgb3 knockdown or genetic loss impaired normal hematopoietic stem and progenitor cell (HSPC) function in 16 week multilineage reconstitution assays. We further identified Itgav as the heterodimeric partner of Itgb3 in our model, and found that knockdown of Itgav inhibited leukemia cell growth in vivo. Consistent the therapeutic aims or our study, flow cytometry on primary human AML samples revealed ITGAV/ITGB3 heterodimer expression. To functionally assess the importance of gene expression in a human system, we performed another RNAi screen on M9 leukemia cells, primary human cord blood CD34+ cells transduced with MLL-ENL that are capable of growing in vitro or in a xenotransplant model in vivo. We found that ITGB3 loss inhibited M9 cell growth in vivo, but not in vitro, consistent with the importance of ITGB3 in a physiologic microenvironment. We explored the signaling pathways downstream of Itgb3 using an additional in vivo, unbiased shRNA screen and identified Syk as a critical mediator of Itgb3 activity in leukemia. Syk knockdown by RNAi inhibited leukemia cell growth in vivo; downregulation of Itgb3 expression resulted in decreased levels of Syk phosphorylation; and expression of an activated form of Syk, TEL-SYK, rescued the effects of Itgb3 knockdown on leukemia cell growth in vivo. To understand cellular processes controlled by Itgb3, we performed gene expression studies and found that, in leukemia cells, Itgb3 knockdown induced differentiation and inhibited multiple previously published LSC transcriptional programs. We confirmed these results using primary leukemia cell histology and a model system of leukemia differentiation. Finally, addition of a small molecule Syk inhibitor, R406, to primary cells co-cultured with bone marrow stroma caused a dose-dependent decrease in leukemia cell growth. Our results establish the significance of the Itgb3 signaling pathway, including Syk, as a potential therapeutic target in AML, and demonstrate the utility of in vivo RNA interference screens. Disclosures: Armstrong: Epizyme: Consultancy.

scholarly journals Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors

Oncotarget ◽  
2017 ◽  
Vol 8 (34) ◽  
pp. 56991-57002 ◽  
Author(s):  
Pavel Spirin ◽  
Timofey Lebedev ◽  
Natalia Orlova ◽  
Alexey Morozov ◽  
Nadezhda Poymenova ◽  
...  
Keyword(s):  
Cell Growth ◽  
Leukemia Cell

MDI 301 suppresses myeloid leukemia cell growth in vitro and in vivo without the toxicity associated with all-trans retinoic acid therapy

2015 ◽  
Vol 26 (7) ◽  
pp. 763-773
Author(s):  
Muhammad N. Aslam ◽  
Shannon McClintock ◽  
Shazli P. Khan ◽  
Patricia Perone ◽  
Ronald Allen ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Cell Growth ◽  
Myeloid Leukemia ◽  
Leukemia Cell ◽  
Acid Therapy ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Myeloid Leukemia Cell

scholarly journals 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities

2019 ◽  
Vol 84 ◽  
pp. 150-163 ◽  
Author(s):  
Marwa Ali A. Fathi ◽  
Amer Ali Abd El-Hafeez ◽  
Dalia Abdelhamid ◽  
Samar H. Abbas ◽  
Monica M. Montano ◽  
...  
Keyword(s):  
Cell Growth ◽  
Leukemia Cell ◽  
Design Synthesis

Photodynamic therapy inhibits cell growth and enhances the histone deacetylase-mediated viability impairment in Cryptococcus spp. in vitro

2020 ◽  
Vol 29 ◽  
pp. 101583
Author(s):  
José Athayde Vasconcelos Morais ◽  
Mosar C. Rodrigues ◽  
Fernanda F. Ferreira ◽  
Kunal Ranjan ◽  
Ricardo Bentes Azevedo ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cell Growth ◽  
Histone Deacetylase ◽  
Cryptococcus Spp

scholarly journals Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

2020 ◽  
Vol 11 (36) ◽  
pp. 9784-9806 ◽  
Author(s):  
John A. Roque ◽  
Patrick C. Barrett ◽  
Houston D. Cole ◽  
Liubov M. Lifshits ◽  
Ge Shi ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Real World ◽  
Anticancer Agent ◽  
Nir Light

A nontoxic Os(ii) oligothienyl complex Os-4T is an extremely potent light-responsive anticancer agent that can be activated in hypoxia and with NIR light.

scholarly journals New Class of Homoleptic and Heteroleptic Bis(terpyridine) Iridium(III) Complexes with Strong Photodynamic Therapy Effects

2019 ◽  
Vol 2 (7) ◽  
pp. 2964-2977 ◽  
Author(s):  
Bingqing Liu ◽  
Susan Monro ◽  
Zhike Li ◽  
Mohammed A. Jabed ◽  
Daniel Ramirez ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
New Class
Sign in / Sign up

Export Citation Format

Share Document